Patients in the low METTL3/YTHDF1 group have a better prognosis, so the combination of METTL3 and YTHDF1 serves as a biomarker reflecting the malignancy and prognostic outcome of hepatocellular carcinoma. This evidence concerns the gene METTL3 and hepatocellular carcinoma.